A new draft report from the Institute for Clinical and Economic Review suggests that PD-L1 immunotherapies exceed commonly used cost-effectiveness thresholds in second-line non-small cell lung cancer, but hedges on this conclusion, and also questions the magnitude of overall survival benefit.
ICER’s Midwest Comparative Effectiveness Public Advisory Council (CEPAC) issued the report – Treatment Options for Advanced Non-Small Cell Lung Cancer:...






